Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

MISSIONTM RNAi: Using siRNA and shRNA to Mediate Gene Silencing

Heather Holemon, R&D Principle Investigator, Functional Genomics Group, Sigma-Aldrich, speaking at RNAi Europe 2007
Date Posted: Friday, March 14, 2008
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

QIAGEN Expands Leadership in Liquid Biopsies
QIAGEN and Tokai Pharmaceuticals to co-develop and commercialize the first regulated CTC-based companion diagnostic to guide treatments in prostate cancer.
Tuesday, March 17, 2015
QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN to Acquire SABiosciences
Transaction adds to QIAGEN’s content engine for development of future diagnostics and boosts the Company’s presence in pharma discovery and validation.
Tuesday, November 10, 2009
Nobel Prize to HPV Researcher Highlights Importance of Cervical Cancer Screening and Prevention
The Nobel Prize-winning discovery of the causal link between human papillomavirus (HPV) and cervical cancer has spurred lifesaving prevention technologies – such as HPV testing and HPV vaccines - that are helping to eradicate cervical cancer globally.
Tuesday, October 07, 2008
Qiagen Forms a User Forum for High-Throughput RNAi Screening
The user forum aims to facilitate advances in RNAi screening in drug target identification and systems biology.
Tuesday, March 28, 2006
Qiagen Develops Leading Solutions for RNA Interference
Qiagen will develop world’s largest collection of validated siRNAs through an extensive validation project.
Tuesday, December 13, 2005
Qiagen Delivers the Human Druggable Genome siRNA Set
This second generation siRNA set enables gene silencing studies of 6992 potential human druggable targets.
Friday, September 30, 2005
Scientific News
Diagnosing Cancer with Help from Bacteria
Engineered probiotics can detect tumors in the liver.
Tumor Microenvironment Impacts Cancer Subtype Progression
Scientists report that two different mouse models of breast cancer progressed differently based on characteristics of the tumor microenvironment, which is the area of tissue in which the tumor is embedded.
Sistemic, RoosterBio Collaborate
This is a collaboration and memorandum of understanding to combine their technologies to advance mesenchymal stem/stromal (MSC) regenerative technology.
‘Rosetta Stone’ for Prostate Cancer Mutations
Scientists have produced a comprehensive genetic map of the mutations in prostate cancer that have spread across the body.
Bioresorbable Electronic Stent Could Provide Feedback, Therapy
Researchers have developed and tested a drug releasing electronic stent which could significantly reduce the risk associated with traditional mesh tube stents.
Researchers use Nanoparticle Tracking Analysis to Study Extracellular Vesicles
Scientists are working to find a way deliver a specific microRNA species capable of retarding the growth of tumor cells.
Two New and Very Large Classes of RNAs Linked to a Cancer Biomarker Identified
Study shows two new classes of RNAs could play a role in progression of prostate cancer.
Master Gene Regulator Could Be New Target For Schizophrenia Treatment
Researchers at MIT’s Picower Institute for Learning and Memory have identified a master genetic regulator that could account for faulty brain functions that contribute to schizophrenia.
Researchers Find “Decoder Ring” Powers in microRNA
MicroRNA can serve as a "decoder ring" for understanding complex biological processes, a team of New York Univ. chemists has found.
Genetic Markers for Detecting and Treating Ovarian Cancer
Custom bioinformatics algorithm identifies human mRNAs that distinguish ovarian cancer cells from normal cells and provide new therapeutic targets
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters